Article

Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A

Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute of Medical Research, University of Cambridge, CB2 0XY, UK.
Nature (Impact Factor: 42.35). 11/2007; 450(7171):887-892. DOI: 10.1038/nature06406

ABSTRACT The major histocompatibility complex (MHC) on chromosome 6 is associated with susceptibility to more common diseases than any other region of the human genome, including almost all disorders classified as autoimmune. In type 1 diabetes the major genetic susceptibility determinants have been mapped to the MHC class II genes

Download full-text

Full-text

Available from: Alexandra S Whale, Dec 12, 2014
4 Followers
 · 
182 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is compelling evidence that autoreactive CD8+ T cells play a central role in precipitating the development of autoimmune diabetes in NOD mice, but the underlying mechanisms remain unclear. Given that CD103 recognizes an islet-restricted ligand (E-cadherin), we postulated that its expression is required for initiation of disease. We herein use a mouse model of autoimmune diabetes (NOD/ShiLt mice) to test this hypothesis. We show that CD103 is expressed by a discrete subset of CD8+ T cells that infiltrate pancreatic islets prior to the development of diabetes. Moreover, we demonstrate that diabetes development in CD103 deficient NODs is significantly delayed at early but not late time points suggesting that CD103 is preferentially involved in early diabetes development. To rule out a potential contribution by closely linked loci to this delay, we treated wild type NODs beginning at 2weeks of age, through 5 weeks of age with a depleting anti-CD103 mAb and found a decreased incidence of diabetes following anti-CD103 mAb treatment compared to isotype control mAbs or non-depleting mAb to CD103. Moreover, a histologic examination of the pancreas of treated mice revealed that NOD mice treated with a depleting mAb were resistant to immune destruction. These data indicate that CD103+ cells play a key role in the development of autoimmune diabetes, and are consistent with the hypothesis that CD103+CD8+ T effectors initiate the disease process.
    Journal of Endocrinology 12/2014; DOI:10.1530/JOE-14-0396 · 3.59 Impact Factor
  • Source
    Type 1 Diabetes - Pathogenesis, Genetics and Immunotherapy, 11/2011; , ISBN: 978-953-307-362-0
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Motivation: Genome-wide association studies are commonly used to identify possible associations between genetic variations and diseases. These studies mainly focus on identifying individual single nucleotide polymorphisms (SNPs) potentially linked with one disease of interest. In this work, we introduce a novel methodology that identifies similarities between diseases using information from a large number of SNPs. We separate the diseases for which we have individual genotype data into one reference disease and several query diseases. We train a classifier that distinguishes between individuals that have the reference disease and a set of control individuals. This classifier is then used to classify the individuals that have the query diseases. We can then rank query diseases according to the average classification of the individuals in each disease set, and identify which of the query diseases are more similar to the reference disease. We repeat these classification and comparison steps so that each disease is used once as reference disease. Results: We apply this approach using a decision tree classifier to the genotype data of seven common diseases and two shared control sets provided by the Wellcome Trust Case Control Consortium. We show that this approach identifies the known genetic similarity between type 1 diabetes and rheumatoid arthritis, and identifies a new putative similarity between bipolar disease and hypertension. Contact: serafim@cs.stanford.edu
    Bioinformatics 07/2009; 25(12):i21-9. DOI:10.1093/bioinformatics/btp226 · 4.62 Impact Factor